WallaceLovellAkerleyIIIMD

Oncology • Salt Lake City, UT

Hematologic Oncology, Thoracic Cancer

Professor of Medicine, University Utah

Join to view full profile

Dr. Akerley is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Akerley's full profile

Already have an account?

Office
1950 Circle of Hope Dr
# Clinic
Salt Lake City, UT 84112
Phone+1 801-585-0100
Is this information wrong?

Education & Training

Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 1985 - 1989
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 1984 - 1985
University of Southern California/LAC+USC Medical CenterResidency, Internal Medicine, 1981 - 1984
The Warren Alpert Medical School of Brown UniversityClass of 1981

Certifications & Licensure

CA State Medical License 1982 - Present
UT State Medical License 2002 - 2026
RI State Medical License 1989 - 2000
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

S0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2002 Jan 01
Completed
Phase 2
Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer Start of enrollment: 2007 Aug 01
Completed
Phase 2
A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2004 Jun 01
Completed
Phase 2
Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer Start of enrollment: 2013 Dec 02
Completed
Phase 1
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Tumor Treating Fields for Locally Advanced NSCLC Start of enrollment: 2024 Apr 04
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

A matching-based machine learning approach to estimating optimal dynamic treatment regimes with time-to-event outcomes.
Xuechen Wang, Hyejung Lee, Benjamin Haaland, Jincheng Shen, Kathleen Kerrigan, Sonam Puri, Wallace Akerley> ;Statistical Methods in Medical Research. 2024 May 1
2 citations
Mesothelioma: Pleural, Version 1.2024.
Loo, B. W., James Stevenson, David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Ch...> ;Journal of the National Comprehensive Cancer Network. 2024 Mar 1
Surgical-decision making in the setting of unsuspected N2 disease: a cost-effectiveness analysis.
Brian Mitzman, Thomas K Varghese Jr, Richard E Nelson, Wallace L Akerley> ;Journal of Thoracic Disease. 2024 Feb 29
Risk factors and health behaviors associated with loneliness among cancer survivors during the COVID-19 pandemic.
Elena S Aßmann, Jennifer Ose, Cassandra A Hathaway, Laura B Oswald, Sheetal Hardikar, Caroline Himbert, Vimalkumar Chellam, Tengda Lin, Bailee Daniels, Anne C Kirchhof...> ;Journal of Behavioral Medicine. 2024 Jun 1
1 citations
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Lin, C., Garralda, E., Schöffski, P., Hong, D., Siu, L., Martin, M., Maur, M., Hui, R., Soo, R., Chiu, J., Zhang, T., Ma, B., Kyi, C., Tan, D., Cassier, P., Sarantopou...> ;Oncoimmunology. 2024 Jan 1
Keeping a track on leptomeningeal disease in non-small cell lung cancer: A single-institution experience with CNSide.
Monynahan, K., Cannon, L., Blouw, B., Puri, S., Malani, R., Chalmers, A., Kerrigan, K., Patel, S., Akerley, W.> ;Neuro-Oncology Advances. 2023 Dec 9
Pathways to lung cancer diagnosis among individuals who did not receive lung cancer screening: a qualitative study.
Rachel D McCarty, Mollie E Barnard, Katherine A Lawson-Michod, Makelle Owens, Sarah E Green, Samantha Derzon, Lea Karabegovic, Wallace L Akerley, Melissa H Watt, Jenni...> ;BMC Primary Care. 2023 Oct 3
Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Chirieac, L. R., Loo, B. W., David S Ettinger, Douglas E Wood, James Stevenson, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y C...> ;Journal of the National Comprehensive Cancer Network. 2023 Sep 1
9 citations
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on o...
Ticiana Leal, Rupesh Kotecha, Rodryg Ramlau, Li Zhang, Janusz Milanowski, Manuel Cobo, Jaromir Roubec, Lubos Petruzelka, Libor Havel, Sujith Kalmadi, Jeffrey Ward, Zor...> ;The Lancet. Oncology. 2023 Sep 1
1 citations
Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042).
Shirish M Gadgeel, Jieling Miao, Jonathan W Riess, James Moon, Philip C Mack, Gregory J Gerstner, Timothy F Burns, Asma Taj, Wallace L Akerley, Konstantin H Dragnev, N...> ;Clinical Cancer Research. 2023 Sep 15
75 citations
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.
Loo, B. W., David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Malcolm D...> ;Journal of the National Comprehensive Cancer Network. 2023 Apr 1
1 citations
A rare FGF5 candidate variant (rs112475347) for predisposition to nonsquamous, nonsmall-cell lung cancer.
Lisa A Cannon-Albright, Craig C Teerlink, Jeff Stevens, Julio C Facelli, Shamus R Carr, Kristina Allen-Brady, Sonam Puri, Joan E Bailey-Wilson, Anthony M Musolf, , Wal...> ;International Journal of Cancer. 2023 Jul 15
1 citations
Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib.
Jarrod T Smith, Sonam Puri, Wallace Akerley> ;Clinical Lung Cancer. 2023 Jun 1
Loss of the endocytic tumor suppressor HD-PTP phenocopies LKB1 and promotes RAS-driven oncogenesis.
Chang-Soo Seong, Chunzi Huang, Austin C Boese, Yuning Hou, Junghui Koo, Janna K Mouw, Manali Rupji, Greg Joseph, H Richard Johnston, Henry Claussen, Jeffrey M Switchen...> ;Biorxiv. 2023 Jan 27
Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer.
Shashank Sama, Kathleen Kerrigan, Jennifer A Sinnott, Sonam Puri, Wallace Akerley, Benjamin Haaland, Shiven Patel> ;Cancer Treatment and Research Communications. 2023 Jan 1
3 citations
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembroli...
Charles M Rudin, Hardev S Pandha, Matthew Zibelman, Wallace L Akerley, Kevin J Harrington, Daphne Day, Andrew G Hill, Steven J O'Day, Timothy D Clay, Gavin M Wright, R...> ;Journal for Immunotherapy of Cancer. 2023 Jan 1
Addendum: Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study.
Connor Willis, Hillevi Bauer, Trang H Au, Jyothi Menon, Sudhir Unni, Dao Tran, Zachary Rivers, Wallace Akerley, Matthew B Schabath, Firas Badin, Ashley Sekhon, Malini ...> ;Oncotarget. 2022 Dec 6
1 citations
Patterns of indoor radon concentrations, radon-hazard potential, and radon testing on a small geographic scale in Utah.
Judy Y Ou, Joemy M Ramsay, Greg Lee, James A VanDerslice, Marissa Taddie, Anne C Kirchhoff, Eleanor Divver, Wallace Akerley, Deanna Kepka, Heidi A Hanson> ;Journal of Environmental Radioactivity. 2023 Jan 1
3 citations
Replicative Instability Drives Cancer Progression.
Benjamin B Morris, Jason P Smith, Qi Zhang, Zhijie Jiang, Oliver A Hampton, Michelle L Churchman, Susanne M Arnold, Dwight H Owen, Jhanelle E Gray, Patrick M Dillon, H...> ;Biomolecules. 2022 Oct 26
6 citations
Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptions.
Anita R Peoples, Laura B Oswald, Jennifer Ose, Bailee Daniels, Caroline Himbert, Cassandra A Hathaway, Biljana Gigic, Anne C Kirchhoff, Tengda Lin, Douglas Grossman, J...> ;The Journal of Rural Health. 2022 Sep 1
7 citations
Factors associated with changes in exercise behaviors during the COVID-19 pandemic.
Caroline Himbert, Cassandra A Hathaway, Bailee Daniels, Karen Salas, Anjelica Ashworth, Biljana Gigic, Tengda Lin, Richard Viskochil, Anne C Kirchhoff, Douglas Grossma...> ;Cancer Causes & Control. 2022 Jul 1
13 citations
A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern.
Kathleen Kerrigan, Yeonjung Jo, Jonathan Chipman, Benjamin Haaland, Sonam Puri, Wallace Akerley, Shiven Patel> ;JTO Clinical and Research Reports. 2022 Mar 1
63 citations
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
Patrick Schöffski, Daniel S W Tan, Miguel Martín, María Ochoa-de-Olza, John Sarantopoulos, Richard D Carvajal, Chrisann Kyi, Taito Esaki, Amy Prawira, Wallace Akerley,...> ;Journal for Immunotherapy of Cancer. 2022 Feb 1
2 citations
Dynamic Prediction of Near-Term Overall Survival in Patients with Advanced NSCLC Based on Real-World Data.
Xuechen Wang, Kathleen Kerrigan, Sonam Puri, Jincheng Shen, Wallace Akerley, Benjamin Haaland> ;Cancers. 2022 Jan 29
2 citations
Adoption of Patient-Generated Health Data in Oncology: A Report From the NCCN EHR Oncology Advisory Group.
Peter D Stetson, Nadine J McCleary, Travis Osterman, Kavitha Ramchandran, Amye Tevaarwerk, Tracy Wong, Jessica M Sugalski, Wallace Akerley, Annette Mercurio, Finly J Z...> ;Journal of the National Comprehensive Cancer Network. 2022 Jan 18
Join now to see all

Press Mentions

Do Low-Grade irAEs with Atezolizumab Predict Survival in Stage IV NSCLC?March 9th, 2023
Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingNovember 10th, 2022
Host Immune Classifier HIC Assays May Predict Treatment ResponseJanuary 30th, 2021
Join now to see all